Drug intelligence / Profile preview

CBP-233

Development stage: Preclinical
Lead developer: Connect Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

CBP-233 is a monoclonal antibody that targets interleukin-33 (IL-33), acting as an IL-33 inhibitor. It was developed by Suzhou Connect Biopharma (Connect Biopharmaceuticals) for the treatment of various serious inflammatory conditions, particularly those involving type 2 inflammation such as allergic and other chronic inflammatory diseases. The drug is currently in preclinical development, with its primary mechanism being the inhibition of IL-33 signaling, which plays a key role in mediating immune responses associated with inflammation[1][2][3][5].

Targets

IL33 (IL-33)

Beyond the preview

Go deeper on CBP-233.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBP-233.

Explore the full profile